Context Capital Management’s Drugs Made In America Acquisition Corp DMAA Stock Holding History

Context Capital Management’s Portfolio DMAA Stock Details DMAA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-250,000	Closed	-$2.62M	–	436
2026 Q1	$2.62M	Hold	250,000	–	–	0.06%	156
2025 Q4	$2.59M	Hold	250,000	–	–	0.07%	136
2025 Q3	$2.57M	Buy	+250,000	New	+$2.56M	0.08%	128

Other funds holding DMAA

KIM

Karpus Investment Management Pittsford, New York $3.48B AUM 10.49% 1-Year Est. Return

MSU

Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

HCM

Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return

FTCM

First Trust Capital Management Chicago, Illinois $1.72B AUM 70.66% 1-Year Est. Return

HCM

Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return

WCMNY

Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return

Context Capital Management's DMAA Position: Q2 2026 in Review

Context Capital Management sold out of Drugs Made In America Acquisition Corp (DMAA) in Q2 2026, closing a stake of 250,000 shares — an estimated $2.62M sold.

Context Capital Management first reported a position in DMAA in Q3 2025 and held it in 3 quarters. The position peaked at $2.62M in Q1 2026. 23 funds tracked by Wall St. Rank hold DMAA as of Q2 2026.

Context Capital Management reported no remaining Drugs Made In America Acquisition Corp position as of Q2 2026 after selling out during the quarter.
Context Capital Management sold 250,000 Drugs Made In America Acquisition Corp shares in Q2 2026, an estimated $2.62M.
Context Capital Management first reported a position in Drugs Made In America Acquisition Corp in Q3 2025 and held it in 3 quarters.
Context Capital Management's Drugs Made In America Acquisition Corp position peaked at $2.62M in Q1 2026.
23 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp as of Q2 2026.

Based on Context Capital Management's 13F filing for Q2 2026, filed 23 Jul 2026.